Combining pure yellow and high-powered infrared laser energy, the ADVATx presents an unparalleled treatment option for pigmented and vascular lesions, active acne, scars, and fine lines and wrinkles, and to improve skin tone and texture, with minimal to no downtime.
The ADVATx laser is touted as the world’s most advanced solid-state yellow vascular laser (589nm) and the first of its kind to incorporate skin rejuvenation (1319nm) to address a wide range of conditions.
This unique, reliable, solid-state laser boasts exceptional patient comfort (without the need for topical anaesthetic), minimal to no downtime or unwanted side effects, and no consumables. TGA listed and FDA/CE cleared for the majority of skin conditions of the most common skin indications, ADVATx offers a truly versatile platform that is redefining the gold standard for Facial laser technology.
With both 589nm and 1319nm available via a single spot or variety of scanned patterns, ADVATx allows practitioners to customise the treatment of red, blue and purple vascular conditions, acne, acne scars, pigmentation and melasma, lines and wrinkles and overall skin rejuvenation with minimal discomfort or adverse effects such as bruising, purpura or scarring. The two wavelengths – which can be used as standalone treatments or combined for multi- faceted skin rejuvenation – are also proving advantageous for what have traditionally been IPL, PDL or standard vascular laser applications, without the discomfort or limitations associated with treating brown and red pigment using IPL.
At the heart of this innovative system is ADVATx’s patented pulse synchronisation, or PulSync, technology. It harnesses the selectivity and utility of the dual wavelengths, whether used alone or in combination, to achieve exceptional outcomes. A shared q-switch modulates both wavelengths to generate a pulsed train of light. These synchronised pulsed trains are then directed through a non-linear crystal, specifically an LBO, which combines the wavelengths of the 1064nm and 1319nm photons. The result is the generation of 589nm, or yellow light. Alternatively, 1319nm may be selected, depending on the treatment goals.
A dramatically more tolerable treatment option
Ensuring patient comfort during and after treatments is a priority, and the ADVATx laser system excels in this aspect, offering minimal,if any, discomfort and downtime without sacrificing efficacy. No topical anesthesia or nerve blocks are required.
ADVATx’s ability to minimise discomfort and damage to surrounding tissue is because of its Quasi CW pulsing, which delivers individual pulses of energy at a repetition rate of 12 kHz.
As the durations of the individual pulses and the pulse-to-pulse spacings are significantly shorter than the thermal relaxation time of the vessels, the skin perceives the multiple pulses of energy as a single pulse. This means that a 20ms pulse of energy can be directed at the target, such as veins, without the trauma to the surrounding tissue caused by the significantly larger energy spikes of a pulsed dye laser. In essence, ADVATx allows for all the well-known therapeutic benefits of yellow light, without the undesirable side effects associated with pulsed dye laser.
Intelligent, intuitive design
The ADVATx is among the most sophisticated dermatology lasers in the world – and it’s also designed to be one of the easiest to operate. With preset treatment parameters for the most common procedures, an easy-to-use intuitive interface, fast start-up time and no consumables, it is simple to operate and easily delegable.
ADVATx is the world’s only medical solid-state laser system that produces both 589nm and 1319nm wavelengths, representing a pivotal advancement in patient comfort without compromising on results. With the ability to treat numerous indications, ranging from vascular abnormalities to acne, wrinkle reduction and skin rejuvenation, this technology is poised to become the laser modality of choice for the modern aesthetic practitioner. AMP
Treatments include:
Skin rejuvenation
Combining 589 and 1319nm wavelengths initiates an inflammatory response by targeting superficial vasculature while at the same time causing thermal injury to the papillary dermis, initiating the body’s natural wound healing response, stimulating fibroblast activity and the formation of Type 1 and 3 collagen, resulting in visible improvement to tone and texture.
Vascular
The ideal ratio of oxyhemoglobin to melanin absorption of 589nm, coupled with the PulSync delivery system, provides for the ability to safely and effectively treat a broad range of vascular abnormalities without patient downtime.
Acne
By targeting the p.acne bacteria itself, the vascular component to active lesions and the underlying oil production by the sebaceous glands, the ADVATx employs a multi-pronged approach to reducing active acne.
Melasma
By addressing the underlying vascular components with 589nm and the sebaceous gland component with 1319nm, melasma is targeted on multiple fronts. The absorption characteristics and delivery mechanism allow treatment with a low risk of PIH.
ADVATx is manufactured by Danish company Advalight and distributed in Australia by Device Consulting. For more information email reception@deviceconsulting.com.au, call 03 9998 2020 or visit www.deviceconsulting.com.au.
